基本信息
浏览量:0
职业迁徙
个人简介
Research Interests
My laboratory focus has been on the role of epigenetics in breast cancer, especially the role of aberrant DNA methylation and histone modifications in hormone resistance using human breast cancer cell lines as a model system. These preclinical studies have advanced to early phase clinical trials assessing the role of epigenetic modifiers for treatment of breast cancer. Through my role as a member and chair of the Breast Committee for the Eastern Cooperative Oncology Group I have served as a co-investigator or lead investigator for a number of practice-changing breast cancer trials. These include trials of optimal endocrine therapy for premenopausal hormone-responsive breast cancer, optimization of endocrine therapy for postmenopausal women, use of taxanes in the adjuvant setting, and utility of trastuzumab for early HER-2 positive breast cancer. As a co-founder of the Translational Breast Cancer Research Consortium (TBCRC) I have contributed to the development of early phase biospecimen-rich translational trials in breast cancer. I am an active participant in the development of evidence-based clinical pathways in breast cancer treatment and helped to spearhead a focus on value of cancer care through the American Society of Clinical Oncology.
Clinical Expertise
Management of breast cancer and conduct of all phases of oncology clinical trials
研究兴趣
论文共 92 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
crossref(2023)
crossref(2023)
crossref(2023)
JOURNAL OF CLINICAL ONCOLOGYno. 16 (2023): 503-503
引用2浏览0引用
2
0
crossref(2023)
crossref(2023)
crossref(2023)
crossref(2023)
Cancer Researchno. 5_Supplement (2023): P2-03
引用0浏览0引用
0
0
Natasha Hunter,Lanell M. Peterson,David A. Mankoff,Mark Muzi,Delphine Chen,William R. Gwin, Shaveta Vinayak,Nancy E. Davidson,Jennifer M. Specht,Hannah Linden
CANCER RESEARCHno. 5 (2023)
引用0浏览0引用
0
0
加载更多
作者统计
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn